BetterLife Pharma (BETRF) Stock Price, News & Analysis

Company Overview

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $0.06 to $0.06
• 50-Day Range: $0.06 to $0.08
• 52-Week Range: $0.05 to $0.13
• Volume: 1,601 shs
• Average Volume: 21,323 shs
• Market Capitalization: $9.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BetterLife Pharma Stock Analysis - MarketRank™

BetterLife Pharma scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BetterLife Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BetterLife Pharma is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BetterLife Pharma is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.05% of the float of BetterLife Pharma has been sold short.

Short Interest Ratio / Days to Cover

BetterLife Pharma has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BetterLife Pharma has recently decreased by 5.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BetterLife Pharma does not currently pay a dividend.

Dividend Growth

BetterLife Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.05% of the float of BetterLife Pharma has been sold short.

Short Interest Ratio / Days to Cover

BetterLife Pharma has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BetterLife Pharma has recently decreased by 5.14%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

BetterLife Pharma has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BetterLife Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BetterLife Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.77% of the stock of BetterLife Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.01% of the stock of BetterLife Pharma is held by institutions.

BETRF Stock Analysis - Frequently Asked Questions

How have BETRF shares performed this year?

BetterLife Pharma's stock was trading at $0.0720 at the beginning of 2025. Since then, BETRF shares have decreased by 11.9% and is now trading at $0.0634.

How do I buy shares of BetterLife Pharma?

Shares of BETRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/12/2025
• Next Earnings (Estimated): 9/23/2025
• Fiscal Year End: 1/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:BETRF
• CIK: 1464165
• Web: www.abetterlifepharma.com
• Phone: 604-221-0595
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.55 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -609.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.04
• Quick Ratio: 0.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: -1.52

Miscellaneous

• Outstanding Shares: 151,840,000
• Free Float: 99,045,000
• Market Cap: $9.20 million
• Optionable: Not Optionable
• Beta: 1.39